Medtronic has been raising its dividend for 47 consecutive years and it offers a high yield now. Bristol Myers Squibb offers ...

The stock's fall snapped a two-day winning streak.

Regeneron Pharmaceuticals is a strong investment with robust growth potential, fueled by FDA approvals and resilient market ...

Zolacabtagene autoleucel is under clinical development by Bristol-Myers Squibb and currently in Phase I for Marginal Zone B-cell Lymphoma.

BMS-986484 is under clinical development by Bristol-Myers Squibb and currently in Phase I for Non-Small Cell Lung Cancer.

This was the stock's second consecutive day of gains.

Almost exactly 10 years after the FDA’s initial FDA approval for Bristol Myers Squibb’s Opdivo as the first PD-1 inhibitor in ...

Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Bristol-Myers ...

The U.S. Food and Drug Administration said on Friday that it has approved an injectable version of Bristol Myers Squibb's ...

Bristol-Myers Squibb has rebounded strongly in 2024, driven by key drug approvals and positive financial performance. See why ...

Bullish option flow detected in Bristol Myers ( BMY) Squibb with 203,938 calls trading, 22x expected, and implied vol increasing over 5 points to 22.90%. Jan-25 52.5 calls and Jan-25 50 calls are the ...

The agency’s main drug review office cleared 50 novel medicines last year, short of 2018’s record total but on the higher end ...